AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8071050 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 190
Study 8071050 — intervention group
Group type: COMPARATOR
Intervention: Comparators (iopamidol and iohexol)
Number of subjects: 190
Study 8071050 — intervention group
Group type: COMPARATOR
Intervention: Iopromide and Comparators
Number of subjects: 190
Study 3338250 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive upright tilting by 60 degrees
Number of subjects: 0
Study 3338250 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive upright tilting by 20 degrees
Number of subjects: 0
Study 3338250 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of supine values and responses to tilting by 60 degrees across four age groups
Number of subjects: 0
Study 31007142 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of myofascial pain syndrome (MPS)
Number of subjects: 29
Study 31358713 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 28
Study 31358713 — intervention group
Group type: COMPARATOR
Intervention: Glass-ionomer cement (GIC)
Number of subjects: 28
Study 28459603 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) algorithm (CL1/CL2)
Number of subjects: 20
Study 28459603 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (OL) conventional pump therapy (OL1/OL2)
Number of subjects: 20
Study 25308195 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based teaching
Number of subjects: 52
Study 25308195 — intervention group
Group type: COMPARATOR
Intervention: Theatre-based teaching
Number of subjects: 52
Study 23786436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in doctors
Number of subjects: 0
Study 23786436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in hospitals
Number of subjects: 0
Study 23786436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in racial equity of treatment
Number of subjects: 0
Study 23786436 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward dialysis
Number of subjects: 0
Study 21542109 — intervention group
Group type: EXPERIMENTAL
Intervention: Genous stent
Number of subjects: 193
Study 21542109 — intervention group
Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 193
Study 18678610 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere insulin
Number of subjects: 126
Study 18678610 — intervention group
Group type: COMPARATOR
Intervention: Technosphere powder (placebo)
Number of subjects: 126
Study 16544213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 11
Study 16544213 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 11
Study 14557959 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1000 mg, single oral dose)
Number of subjects: 217
Study 14557959 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (500 mg, single oral dose)
Number of subjects: 217
Study 10928293 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mMol/day salt intake
Number of subjects: 55
Study 10928293 — intervention group
Group type: COMPARATOR
Intervention: 150 mMol/day salt intake
Number of subjects: 55
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphasis on item information during study
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphasis on associative information during study
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast presentation rates
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow presentation rates
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: High word concreteness
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low word concreteness
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: High word frequency
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low word frequency
Number of subjects: 0
Study 8881323 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of confidence and response latency
Number of subjects: 0
Study 8097733 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms, subcutaneously)
Number of subjects: 0
Study 8097733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3710012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (225 micrograms)
Number of subjects: 12
Study 3710012 — intervention group
Group type: COMPARATOR
Intervention: Saline (154 mmol/l)
Number of subjects: 12
Study 31881621 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen
Number of subjects: 85
Study 31881621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 29990584 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Mindfulness-Based Stress Reduction (MBSR) course (N=32)
Number of subjects: 97
Study 29990584 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (N=35)
Number of subjects: 97
Study 27916047 — intervention group
Group type: COMPARATOR
Intervention: 20 mg atorvastatin (standard group)
Number of subjects: 120
Study 27916047 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin (intensive group)
Number of subjects: 120
Study 24203849 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (rPerC)
Number of subjects: 443
Study 24203849 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 443
Study 22525762 — intervention group
Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel bid
Number of subjects: 242
Study 22525762 — intervention group
Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel tid
Number of subjects: 242
Study 22525762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 22525762 — intervention group
Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel bid or tid
Number of subjects: 242
Study 22525762 — intervention group
Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel
Number of subjects: 242
Study 20186018 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy healing modalities (Reiki, therapeutic touch, healing touch)
Number of subjects: 0
Study 17512301 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training until a predefined expert level of performance was reached
Number of subjects: 13
Study 17512301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 16271786 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of maximal androgen deprivation (MAD)
Number of subjects: 818
Study 16271786 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of maximal androgen deprivation (MAD)
Number of subjects: 818
Study 16271786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 months of maximal androgen deprivation (MAD)
Number of subjects: 818
Study 16271786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MAD)
Number of subjects: 818
Study 12009244 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP regimen (vindesine 3 mg/m² on days 1 and 8, ifosfamide 1300 mg/m² on days 1-5, cisplatin 20 mg/m² on days 1-5)
Number of subjects: 132
Study 12009244 — intervention group
Group type: COMPARATOR
Intervention: VP regimen (vindesine and cisplatin with the same dose and schedule as VIP)
Number of subjects: 132
Study 12009244 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP regimen
Number of subjects: 132
Study 12009244 — intervention group
Group type: COMPARATOR
Intervention: VP regimen
Number of subjects: 132
Study 10047931 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine at doses of 100 to 300 mg/d
Number of subjects: 14
Study 7497673 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current
Number of subjects: 271
Study 7497673 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive coupled electrical stimulation
Number of subjects: 271
Study 7497673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft surgery
Number of subjects: 271
Study 2022202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stress (cryotherapy)
Number of subjects: 7
Study 2022202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stress (cold immersion)
Number of subjects: 7
Study 2022202 — intervention group
Group type: COMPARATOR
Intervention: Control (air at neutral temperatures)
Number of subjects: 7
Study 6972449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampullometrogram (AMG) in patients with normal CMG
Number of subjects: 20
Study 6972449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampullometrogram (AMG) in patients with hyporeflexic CMG
Number of subjects: 20
Study 6972449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampullometrogram (AMG) in patients with hyperreflexic CMG
Number of subjects: 20
Study 31081862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of 110-139 mm Hg)
Number of subjects: 870
Study 31081862 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of 140-179 mm Hg)
Number of subjects: 870
Study 28088223 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated treatment
Number of subjects: 50
Study 28088223 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 50
Study 25305506 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-proficient tumors with BRAF(V600E) mutations
Number of subjects: 2720
Study 25305506 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-proficient tumors with KRAS mutations
Number of subjects: 2720
Study 25305506 — intervention group
Group type: COMPARATOR
Intervention: MMR-deficient sporadic or familial subtypes
Number of subjects: 2720
Study 25305506 — intervention group
Group type: COMPARATOR
Intervention: MMR-proficient tumors without BRAF(V600E) or KRAS mutations
Number of subjects: 2720
Study 24079817 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous intranasal corticosteroid (INS) formulation
Number of subjects: 185
Study 24079817 — intervention group
Group type: COMPARATOR
Intervention: Aerosol intranasal corticosteroid (INS) formulation
Number of subjects: 185
Study 24079817 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) scale
Number of subjects: 185
Study 24079817 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction subscales
Number of subjects: 185
Study 24079817 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life scales
Number of subjects: 185
Study 21865946 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (CRT)
Number of subjects: 132
Study 21865946 — intervention group
Group type: COMPARATOR
Intervention: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutation
Number of subjects: 132
Study 21865946 — intervention group
Group type: COMPARATOR
Intervention: cyclin D1 G870A (AA) polymorphism
Number of subjects: 132
Study 21865946 — intervention group
Group type: COMPARATOR
Intervention: methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism
Number of subjects: 132
Study 21865946 — intervention group
Group type: COMPARATOR
Intervention: Combination of p53 and v-Ki-ras2 mutations
Number of subjects: 132
Study 21865946 — intervention group
Group type: COMPARATOR
Intervention: Combination of p53 and either v-Ki-ras2 mutation or cyclin D1 G870A (AA) polymorphism or methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism
Number of subjects: 132
Study 21865946 — intervention group
Group type: COMPARATOR
Intervention: Biomarker combinations
Number of subjects: 132
Study 19262477 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan + Calcium Channel Blocker (ARB/CCB group)
Number of subjects: 4000
Study 19262477 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan + Diuretic (ARB/diuretic group)
Number of subjects: 4000
Study 16752259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic supravaginal hysterectomy (LSH)
Number of subjects: 47
Study 16752259 — intervention group
Group type: COMPARATOR
Intervention: Abdominal supravaginal hysterectomy (ASH)
Number of subjects: 47
Study 15209599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for patients presenting with physical symptoms
Number of subjects: 200
Study 15209599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for patients presenting with psychological symptoms
Number of subjects: 200
Study 15209599 — intervention group
Group type: COMPARATOR
Intervention: Usual care for patients presenting with physical symptoms
Number of subjects: 200
Study 11737955 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (100 mg dl-alpha-tocopheryl acetate, 200 mg ascorbic acid, 2 mg beta-carotene)
Number of subjects: 20
Study 11737955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9442997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behaviour Scales and EASE
Number of subjects: 43
Study 9442997 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant differences
Number of subjects: 43
Study 8112368 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine as a single agent
Number of subjects: 12
Study 8112368 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine with metoclopramide (10 mg IV)
Number of subjects: 12
Study 8112368 — intervention group
Group type: COMPARATOR
Intervention: Didanosine with loperamide (4 doses of 4 mg each)
Number of subjects: 12
Study 8112368 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 12
Study 8112368 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine with metoclopramide
Number of subjects: 12
Study 8112368 — intervention group
Group type: COMPARATOR
Intervention: Didanosine with loperamide
Number of subjects: 12
Study 3803193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviewing using the randomized response technique (RRT)
Number of subjects: 0
Study 3803193 — intervention group
Group type: COMPARATOR
Intervention: Direct questioning
Number of subjects: 0
Study 30796122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0
Study 30796122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30187864 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO‐EoN
Number of subjects: 120
Study 30187864 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO‐moisturizer
Number of subjects: 120
Study 30187864 — intervention group
Group type: COMPARATOR
Intervention: All groups (A/BPO regimens)
Number of subjects: 120
Study 27640067 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg SCH 527123
Number of subjects: 13
Study 27640067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23872939 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) - one 60-min bout at 60%-75% of heart rate reserve performed before breakfast
Number of subjects: 9
Study 23872939 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 9
Study 23872939 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 9
Study 22119219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L PEG+ascorbic acid
Number of subjects: 339
Study 22119219 — intervention group
Group type: COMPARATOR
Intervention: 4-L PEG
Number of subjects: 339
Study 20102922 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg once per day
Number of subjects: 16
Study 20102922 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg once per day
Number of subjects: 16
Study 20102922 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 16
Study 20102922 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 16
Study 18929024 — intervention group
Group type: EXPERIMENTAL
Intervention: TopChair (stair-climbing power wheelchair)
Number of subjects: 25
Study 18929024 — intervention group
Group type: COMPARATOR
Intervention: Storm3 (conventional power wheelchair)
Number of subjects: 25
Study 15823184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beclomethasone dipropionate 250 microg b.i.d and slow-release theophylline 0.2 g b.i.d (SRT/BDP group)
Number of subjects: 41
Study 15823184 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 500 microg b.i.d (BDP group)
Number of subjects: 41
Study 11952058 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 dBA intermittent and unpredictable sound-burst condition
Number of subjects: 20
Study 11952058 — intervention group
Group type: COMPARATOR
Intervention: 50 dBA white noise condition
Number of subjects: 20
Study 10614676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 100
Study 10614676 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined 2 mg estradiol and 1 mg norethisterone acetate (E+NETA) daily
Number of subjects: 100
Study 8540760 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 50 mg, 100 mg, 200 mg combined with Didanosine 67 mg, 167 mg, 250 mg
Number of subjects: 11
Study 1784148 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (specific drugs not mentioned)
Number of subjects: 0
Study 1784148 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitized images for quantification
Number of subjects: 0
Study 1784148 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical color models
Number of subjects: 0
Study 7092500 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule for Affective Disorders and Schizophrenia‐Lifetime (SADS‐L)
Number of subjects: 42
Study 7092500 — intervention group
Group type: COMPARATOR
Intervention: National Institute for Mental Health Diagnostic Interview Schedule (NIMH‐DIS)
Number of subjects: 42
Study 7092500 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SADS‐L and NIMH‐DIS
Number of subjects: 42
Study 30840551 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC‐NOSF dressing with poly‐absorbent fibres
Number of subjects: 88
Study 27356944 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking training
Number of subjects: 30
Study 27356944 — intervention group
Group type: COMPARATOR
Intervention: Forward walking training
Number of subjects: 30
Study 27730198 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 µg
Number of subjects: 1037
Study 27730198 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium 50 µg
Number of subjects: 1037
Study 24284985 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% cis-urocanic acid emulsion cream
Number of subjects: 45
Study 24284985 — intervention group
Group type: COMPARATOR
Intervention: Control vehicle
Number of subjects: 45
Study 23126345 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood pressure measurement device
Number of subjects: 225
Study 23126345 — intervention group
Group type: COMPARATOR
Intervention: Manual blood pressure measurement device
Number of subjects: 225
Study 23126345 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive visits (3 visits)
Number of subjects: 225
Study 23126345 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive visits (7 visits)
Number of subjects: 225
Study 23126345 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive visits (18 visits)
Number of subjects: 225
Study 23126345 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 visits spread over 4 years
Number of subjects: 225
Study 23126345 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blood pressure measurement per visit
Number of subjects: 225
Study 19156355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (up to 1.2 mg/kg/day or 80 mg/day) with psychoeducation
Number of subjects: 99
Study 19156355 — intervention group
Group type: COMPARATOR
Intervention: Placebo with psychoeducation
Number of subjects: 99
Study 19156355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (with psychoeducation)
Number of subjects: 99
Study 19156355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with psychoeducation)
Number of subjects: 99
Study 18087899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine/evening primrose
Number of subjects: 80
Study 18087899 — intervention group
Group type: COMPARATOR
Intervention: Low Intensity Laser Therapy (LILT)
Number of subjects: 80
Study 16023298 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 0
Study 16023298 — intervention group
Group type: COMPARATOR
Intervention: Duoderm
Number of subjects: 0
Study 12616983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive preparations (30 micrograms ethinylestradiol with either 75 micrograms gestodene or 150 micrograms desogestrel)
Number of subjects: 77
Study 12616983 — intervention group
Group type: COMPARATOR
Intervention: 17 beta-oestradiol (2 mg)
Number of subjects: 77
Study 12616983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive preparations (30 micrograms ethinylestradiol)
Number of subjects: 77
Study 10721054 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP)
Number of subjects: 0
Study 10721054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8819814 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 150‐300 mg/die
Number of subjects: 170
Study 8819814 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 450‐900 mg/die
Number of subjects: 170
Study 8819814 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 170
Study 8819814 — intervention group
Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 170
Study 2048373 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation (N = 5)
Number of subjects: 18
Study 2048373 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation and imagery (N = 4)
Number of subjects: 18
Study 2048373 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (N = 5)
Number of subjects: 18
Study 2048373 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group (N = 4)
Number of subjects: 18
Study 2048373 — intervention group
Group type: COMPARATOR
Intervention: Assessment control group during baseline periods (N = 4)
Number of subjects: 18
Study 2048373 — intervention group
Group type: COMPARATOR
Intervention: Psychological stress (prospective control group)
Number of subjects: 18
Study 6127888 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 0